A Business at a Glance
0 of 5 daily views used (5 remaining). Sign up free for 10 daily views, or try AAPL for a full preview.
ITEM 1. BUSINESS We are an early-clinical-stage therapeutics company focused on developing treatments for adult and pediatric cancer. Our business now consists of one early-clinical-stage therapeutic program (QN-302) and one preclinical therapeutic program (Pan-RAS). In addition, on April 11, 2024, we entered into a Co-Development Agreement (the “Co-Development Agreement”) with Marizyme, Inc. (“Marizyme”). The Co-Development Agreement contemplated that we would invest an aggregate of $800,000 in Marizyme in April 2024 (the “Funding Payment”) and pay Marizyme a $200,000 Exclusivity Fee (Provided, that if the parties so agree the total Funding Payment can be increased from time to time to up to a total of $1,500,000.
| Metric | TTM | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | 0 | - | - | - | - |
| Net Income | -8.1M | -13M | -19M | -18M | -20M |
| EPS | $3.03 | $-123.00 | $-181.00 | $-305.00 | $-585.00 |
| Free Cash Flow | 0 | -10M | -13M | -15M | - |
| ROIC | -13.0% | -439.2% | -628.8% | -102.7% | -55.4% |
| Gross Margin | - | - | - | - | - |
| Debt/Equity | 0.08 | -0.62 | 0.13 | 0.01 | 0.01 |
| Dividends/Share | $0.00 | - | - | - | - |
| Operating Income | -7.2M | -11M | -15M | -23M | -20M |
| Operating Margin | 0.0% | - | - | - | - |
| ROE | -21.0% | -522.9% | -257.6% | -102.7% | -210.6% |
| Shares Outstanding | 5M | 0M | 0M | 0M | 0M |
| Metric | 2020 | 2021 | |||
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | N/A | N/A | N/A | N/A | 0 |
| Gross Margin | N/A | N/A | N/A | N/A | N/A |
| R&D | N/A | 12M | 4.5M | 5.2M | 112K |
| SG&A | N/A | 12M | 10M | 6.1M | 6.8M |
| EBIT | -20M | -23M | -15M | -11M | -7.2M |
| Op. Margin | N/A | N/A | N/A | N/A | 0.0% |
| Net Income | -20M | -18M | -19M | -13M | -8.1M |
| Net Margin | N/A | N/A | N/A | N/A | 0.0% |
| Non-Recurring | 0 | 0 | 4.2M | 4.2M | 0 |
| Returns on Capital | |||||
| ROIC | -55.4% | -102.7% | N/M | N/M | -13.0% |
| ROE | -210.6% | -102.7% | -257.6% | -522.9% | -21.0% |
| ROA | -127.9% | -68.9% | -97.7% | -127.1% | -18.6% |
| Cash Flow | |||||
| Op. Cash Flow | 0 | -15M | -13M | -10M | -7.1M |
| Free Cash Flow | N/A | -15M | -13M | -10M | 0 |
| Owner Earnings | -6.1M | -20M | -18M | -11M | -7.1M |
| CapEx | 0 | 134K | 165K | 0 | 0 |
| Maint. CapEx | 3.4M | 113K | 153K | 4K | 4K |
| Growth CapEx | N/A | 21K | 12K | N/A | 0 |
| D&A | 3.4M | 113K | 153K | 4K | 4K |
| CapEx/OCF | N/A | N/A | N/A | N/A | 0.0% |
| Capital Allocation | |||||
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Dividend Yield | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | 0 | 0 | 0 | 0 | 0 |
| Buyback Yield | 0.0% | 0.0% | 0.0% | N/A | 0.0% |
| Stock-Based Comp | 2.7M | 5.3M | 4.8M | 1.1M | 9K |
| Debt Repayment | 0 | 0 | 0 | 0 | 0 |
| Balance Sheet | |||||
| Net Debt | -24M | -9.0M | -5.4M | 496K | -74M |
| Cash & Equiv. | 24M | 9.2M | 3.2M | 402K | 78M |
| Long-Term Debt | N/A | N/A | N/A | N/A | 3.2M |
| Debt/Equity | 0.01 | 0.01 | 0.13 | -0.62 | 0.08 |
| Interest Coverage | N/A | -530.8 | -429.1 | -18.1 | -18.1 |
| Equity | 18M | 17M | 7.2M | -2.1M | 39M |
| Total Assets | 29M | 23M | 19M | 2.0M | 43M |
| Total Liabilities | 11M | 6.3M | 10M | 6.2M | 42K |
| Intangibles | 188K | 171K | N/A | N/A | N/A |
| Retained Earnings | -67M | -85M | -103M | -117M | -129M |
| Working Capital | N/A | N/A | N/A | N/A | N/A |
| Current Assets | N/A | N/A | N/A | N/A | N/A |
| Current Liabilities | N/A | N/A | N/A | N/A | N/A |
| Per Share Data | |||||
| EPS | -585.00 | -305.00 | -181.00 | -123.00 | 3.03 |
| Owner EPS | -174.05 | -2,853.15 | -176.39 | -104.57 | -1.38 |
| Book Value | 524.06 | 2,346.93 | 70.26 | -19.28 | 7.47 |
| Cash Flow/Share | N/A | -2,087.09 | -128.63 | -94.46 | -1.57 |
| Dividends/Share | N/A | N/A | N/A | N/A | 0.00 |
| Shares Out. | 0.0M | 0.0M | 0.1M | 0.1M | 5.2M |
| Valuation | |||||
| P/E Ratio | N/A | N/A | N/A | N/A | 0.4 |
| P/FCF | N/A | N/A | N/A | N/A | N/A |
| EV/EBIT | N/A | N/A | N/A | N/A | N/A |
| Price/Book | N/A | N/A | N/A | N/A | 0.2 |
| Price/Sales | N/A | N/A | N/A | N/A | N/A |
| FCF Yield | N/A | N/A | N/A | -295.4% | N/A |
| Market Cap | 0 | 0 | 0 | 3.5M | 7.0M |
| Avg. Price | 0.00 | 0.00 | 0.00 | 49.58 | 1.35 |
| Year-End Price | 0.00 | 0.00 | 0.00 | 27.65 | 1.35 |
AIxCrypto Holdings, Inc. passes 0 of 9 quality checks, indicating weak fundamentals.
AIxCrypto Holdings, Inc. (AIXC) has a 5-year average return on invested capital (ROIC) of -79.0%. This is below average and may indicate limited pricing power.
AIxCrypto Holdings, Inc. (AIXC) has a market capitalization of $7M. It is classified as a small-cap stock.
AIxCrypto Holdings, Inc. (AIXC) does not currently pay a regular dividend.
AIxCrypto Holdings, Inc. (AIXC) operates in the Finance Services industry, within the Financials sector.
AIxCrypto Holdings, Inc. (AIXC) generated $-10 million in free cash flow in its most recent fiscal year. Negative free cash flow may indicate heavy investment or operational challenges.
AIxCrypto Holdings, Inc. (AIXC) reported earnings per share (EPS) of $-123.00 in its most recent fiscal year.
AIxCrypto Holdings, Inc. (AIXC) has a return on equity (ROE) of -522.9%. A negative ROE may indicate losses or negative equity.
The Ledger Terminal provides 4 years of financial data for AIxCrypto Holdings, Inc. (AIXC), sourced directly from SEC EDGAR filings. This includes income statements, balance sheets, cash flow statements, and key financial ratios.
AIxCrypto Holdings, Inc. (AIXC) has a book value per share of $-19.28, based on its most recent annual SEC filing.